We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New COVID-19 Assay Proves as Reliable as Laboratory PCR Test and Ideal for Inexpensive POC Diagnosis

By LabMedica International staff writers
Posted on 04 Jan 2022
Print article
Illustration
Illustration

A potential at-home COVID-19 test is just as good as laboratory PCR tests, according to preclinical data.

Researchers at the University of Illinois Chicago (Chicago, IL, USA) have designed a high-quality assay that can be used in at-home tests for rapid COVID-19 screening. Results from an early preclinical study suggest that tests with the new assay may be just as reliable as the laboratory-based molecular tests - called PCR tests - used by hospitals for clinical diagnostics.

Assay reagents create a chemical reaction when mixed with a biological sample containing a virus or other marker. For example, an at-home pregnancy test consists of assay reagents that react to pregnancy hormones in a urine sample. In laboratory molecular tests, scientists mix samples with assay reagents in a highly controlled process. Because the reaction conditions (like temperature) are tightly controlled, the tests are both sensitive and selective, meaning the chance of false positives or false negatives is very low. However, these laboratory tests can be expensive and are not accessible in all communities and field settings. The challenge with at-home and field tests is that they need assay reagents to work under less controlled conditions, which increases the chances for false results or inconclusive tests.

One method, called loop-mediated isothermal amplification (LAMP), which uses six DNA primers for pathogen detection, has shown promise for other pathogens, like malaria, but has not been efficiently applied to COVID-19. The UIC researchers who developed the new COVID-19 assay first created and applied a bioinformatics algorithm to identify the best potential DNA primer combinations for reliably detecting SARS-CoV-2, the virus that causes COVID-19, with the LAMP method. Then, the researchers ran a series of simulations to optimize the conditions under which the potential DNA primer combinations worked best in the field environments.

After using their analysis to develop a testing method using the DNA primers and conditions, the team designed experiments to see how the test performed. In experiments, the researchers processed artificial samples and human samples with a standard PCR test and with their new test. When the results were compared, the researchers not only saw significant improvement in the efficiency of their test over others using the LAMP method to detect the virus but also that it was comparable to more expensive gold standard PCR tests. The researchers concluded that the new LAMP assays were as effective as standard PCR assays in SARS-CoV-2 detection and that their new assays have unique advantages, like speed and direct detection of viral RNA in saliva, that make the test “ideal for inexpensive point-of-care diagnosis.”

The lab-based study showed that their test works, but the researchers will need to validate the test in further studies with a greater number of samples from real patients. They hope that by summer they will have conducted a study including about 1,500 patient samples. If the study validates the test, the data will be submitted with an application to U.S. Food and Drug Administration for Emergency Use Authorization.

“Having fast and easy-to-use tests for COVID-19 is critical, especially in the communities that have low rates of vaccination and low access to health care services, including COVID-19 surveillance and diagnostic testing,” said Xiaowei Wang, UIC professor of pharmacology and bioengineering. “The current crisis has created an unprecedented need for rapid tests that are highly sensitive and the sooner we can develop better technology and testing options, the better it will be for everyone.”

Related Links:
University of Illinois Chicago 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS-CoV-2 Test
One Step SARS-CoV-2 Nucleic Acid Detection Kit (P761H)

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: Molecular PCR-grade detection of Lyme bacteria right at the tick bite (Photo courtesy of En Carta Diagnostics)

Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes

Lyme disease, transmitted through tick bites, is a bacteria-caused illness that impacts 1.2 million individuals annually. The standard methods for diagnosing this disease include clinical examinations,... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more